Discussing Recent Advances and Clinical Trials in Bladder Cancer
Matthew Galsky, MD, discusses the most recent data in patients with bladder cancer.
Matthew Galsky, MD, professor of medicine, director of Genitourinary Medical Oncology, director of the Novel Therapeutics Unit, and codirector of the Center of Excellence for Bladder Cancer at The Tisch Cancer Institute and the Icahn School of Medicine at Mount Sinai, discusses the most recent data in patients with bladder cancer.
Galsky says that it has been a busy time for drug development in the bladder cancer setting. Within the last year, multiple large clinical trials have announced their data for these patients in hopes of changing practice for the frontline treatment of patients with metastatic urothelial cancer.
There was the first read out of the IMvigor130 trial (NCT02807636), which combined platinum-based chemotherapy and the immune checkpoint blockade atezolizumab (Tecentriq) versus atezolizumab monotherapy or chemotherapy and placebo. This study showed an improvement in progression-free survival with the combination, and the overall survival demonstrated a numerical improvement, although it has not reached significance yet, according to Galsky.
The KEYNOTE-361 study (NCT02853305) tested the combination of chemotherapy and pembrolizumab (Keytruda) compared with chemotherapy alone or pembrolizumab alone. Galsky says that based on a press release, this trial did not meet its primary end point, which was disappointing.
At the 2020 American Society of Clinical Oncology Annual Virtual Scientific Meeting plenary session, JAVELIN Bladder 100 trial (NCT02603432) results were presented. In patients who have stable disease after receiving platinum chemotherapy in the first line, investigators looked at maintenance with avelumab (Bavencio) versus the best supportive care, which Galsky explains is observation in this setting. The data showed a significant improvement in progression-free survival and the overall survival with avelumab and this study is likely to change the standard of care.
FDA Approves Nogapendekin Alfa Inbakicept for BCG-Unresponsive NMIBC Carcinoma In Situ
April 22nd 2024Patients with Bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer carcinoma in situ now have a new treatment option following the FDA’s approval of nogapendekin alfa.
Read More
FDA Accepts IND for UGN-103 in Low-Grade Intermediate-Risk NMIBC
April 15th 2024An investigational new drug application for UGN-103 was accepted by the FDA. A phase 3 study to assess the safety and efficacy of the agent in low-grade intermediate-risk non-muscle invasive bladder cancer is anticipated.
Read More
